Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01529346 · ClinicalTrials.gov registry record · Phase 2
Efficacy Of PF-05089771 In Treating Postoperative Dental Pain
A Phase 2 study of Postoperative Dental Pain, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 235
- Enrollment target
- 3
- Study locations
NCT01529346: Completed Phase 2 study of Postoperative Dental Pain, sponsored by Pfizer.
NCT01529346 is a Phase 2 study of Postoperative Dental Pain that has completed, run by Pfizer. The registered enrollment target is 235 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% higher). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01529346, a Phase 2 study of Postoperative Dental Pain, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 235 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objective of this study is to evaluate the overall pain relief of a single dose of PF-05089771 against placebo following third molar extraction.
Primary Outcome
TOTPAR(6) was defined as the total area under pain relief (PR) curve through first 6 hours after dosing, calculated using trapezoidal rule. PR was assumed to be 0 at 0 hour. PR assessed on a 5-point categorical scale: 0(none), 1 (a little), 2 (some), 3 (a lot) and 4 (complete), at different time points during study up to 6 hours. Total score range for TOTPAR(6): 0 (worst) to 24 (best), higher value indicated greater degree of PR. Posterior mean, standard deviation were estimated based on analysi
Conditions Studied
Interventions
- OTHER Placebo
- DRUG PF-05089771
Study Locations (3)
Texas
- Central Texas Oral Surgery Associates - Austin
- Premier Research Group Limited - Austin
- PPD Development, LP - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2011-12-12 |
| Est. Completion | 2012-06-25 |
| Phase | Phase 2 |
What the finished NCT01529346 record still lists
NCT01529346 is an interventional study that assigns participants to a tested intervention. The registered 235 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% higher).
The record links to 1 condition, with Postoperative Dental Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01529346 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01529346 about?
NCT01529346 is a clinical study titled "Efficacy Of PF-05089771 In Treating Postoperative Dental Pain". The objective of this study is to evaluate the overall pain relief of a single dose of PF-05089771 against placebo following third molar extraction.
What is the current status of trial NCT01529346?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 235 participants. The study started on 2011-12-12. Estimated completion is 2012-06-25.
What conditions does trial NCT01529346 study?
This clinical trial studies the following conditions: Postoperative Dental Pain.
What interventions are being tested in trial NCT01529346?
The interventions under investigation include: Placebo (OTHER), PF-05089771 (DRUG).
Who is sponsoring clinical trial NCT01529346?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01529346 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01529346's enrollment target sits among peer trials
235 255th of 2000 higher than 1,746 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01524211 · 235 participants · NA
Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms
- NCT05316155 · 235 participants · Phase 1
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
- NCT05353569 · 235 participants · NA
Coherent Optical Detection of Middle Ear Disease
- NCT05390918 · 235 participants · NA
Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI